Drug Discovery

Breakthrough in Transthyretin Structure Could Revolutionize ATTR Treatment
Research & Development Breakthrough in Transthyretin Structure Could Revolutionize ATTR Treatment

Recent research led by scientists at Scripps Research has unveiled groundbreaking insights into the structure and behavior of the protein transthyretin, which could have significant implications for the treatment of transthyretin amyloidosis (ATTR). This disease, marked by the misfolding of

Can Vero Cells Expressing KREMEN1 Enable CVA6 Vaccine Development?
Biotech & Bioprocessing Can Vero Cells Expressing KREMEN1 Enable CVA6 Vaccine Development?

The increasing prevalence of Coxsackievirus A6 (CVA6) as a major causative agent for Hand, Foot, and Mouth Disease (HFMD) worldwide necessitates the development of an effective vaccine, especially since there is currently no vaccine available against CVA6 infections. CVA6 infections pose a

Transformative Trends in Biopharma: Preparing for 2025 and Beyond
Management & Regulatory Transformative Trends in Biopharma: Preparing for 2025 and Beyond

The biopharma industry stands at a transformative juncture as it reflects on the achievements of the past year and anticipates the evolving client requirements that will shape 2025 and beyond. Key insights from Subodh Deshmukh, CEO of Aragen Bioscience, highlight the crucial areas of focus for

Can Thermo Fisher's Accelerator Platform Revolutionize Drug Development?
Management & Regulatory Can Thermo Fisher's Accelerator Platform Revolutionize Drug Development?

Thermo Fisher Scientific is taking bold steps toward revolutionizing drug development through its innovative Accelerator Drug Development program. This strategy aims to streamline the complex process from preclinical stages to commercialization by integrating its contract research organization

Can Efruxifermin Offer New Hope for MASH-Induced Liver Cirrhosis?
Research & Development Can Efruxifermin Offer New Hope for MASH-Induced Liver Cirrhosis?

The potential breakthrough in treating liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) has come from a recent study by Akero Therapeutics. Efruxifermin, an experimental drug, has shown significant promise in reversing liver damage in patients suffering from this

Can AI Make Precision Medicine Mainstream in Modern Healthcare?
Tech & Innovation Can AI Make Precision Medicine Mainstream in Modern Healthcare?

Precision Medicine (PM), also known as personalized medicine, tailors medical treatments to individual characteristics, specifically focusing on genetic profiles. The intersection of PM and Artificial Intelligence (AI) is accelerating the adoption and effectiveness of precision medicine, addressing

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later